official impact factor

2.93

Advanced search

From basic research to clinical development of MEK1/2 inhibitors for cancer therapy

Christophe Frémin and Sylvain Meloche^*

* Corresponding author: Sylvain Meloche sylvain.meloche@umontreal.ca

Journal of Hematology & Oncology 2010, 3:8 doi:10.1186/1756-8722-3-8

Accesses

Last 30 days: 216 accesses
Last 365 days: 3203 accesses
All time: 7097 accesses

Cited by

BioMed Central: 3 citations

Current management and novel agents for malignant melanoma

Byung Lee, Nikhil Mukhi, Delong Liu Journal of Hematology & Oncology 2012, 5:3 (14 February 2012)

Abstract | Full text | PDF | PubMed | Cited on BioMed Central

A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome

Guoqing Wei, Wanmao Ni, Jen-wei Chiao, Zhen Cai, He Huang, Delong Liu Journal of Hematology & Oncology 2011, 4:46 (14 November 2011)

Abstract | Full text | PDF | PubMed

Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights

Xiongpeng Zhu, Yuehua Ma, Delong Liu Journal of Hematology & Oncology 2010, 3:17 (23 April 2010)

Abstract | Full text | PDF | PubMed | Cited on BioMed Central

Google Scholar: View citations

ISI Web of Science: View citations

PubMed Central: View citations